Ventavis(iloprost)
Aurlumyn, Ventavis (iloprost) is a small molecule pharmaceutical. Iloprost was first approved as Ventavis on 2003-09-15. It is used to treat pulmonary hypertension in the USA. It has been approved in Europe to treat pulmonary hypertension. The pharmaceutical is active against prostacyclin receptor. In addition, it is known to target prostaglandin E2 receptor EP4 subtype, prostaglandin E2 receptor EP2 subtype, prostaglandin E2 receptor EP3 subtype, prostaglandin D2 receptor, thromboxane A2 receptor, prostaglandin F2-alpha receptor, and prostaglandin E2 receptor EP1 subtype.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| respiratory tract diseases | D012140 |
| cardiovascular diseases | D002318 |
Trade Name
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| pulmonary hypertension | EFO_0001361 | D006976 | I27.20 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| Q4074 | Iloprost, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, up to 20 micrograms |
Clinical
Clinical Trials
101 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | 3 | 13 | 11 | 10 | 24 | 57 |
| Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | 2 | 11 | 7 | 6 | 16 | 39 |
| Pulmonary arterial hypertension | D000081029 | — | — | 1 | 3 | 5 | 5 | 19 | 32 |
| Familial primary pulmonary hypertension | D065627 | — | I27.0 | 1 | 3 | 4 | 2 | 11 | 20 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | 3 | — | 1 | 2 | 6 |
| Obstructive lung diseases | D008173 | HP_0006536 | — | — | 3 | — | 1 | 2 | 6 |
| Lung diseases | D008171 | HP_0002088 | J98.4 | — | 2 | — | 1 | 2 | 5 |
| Ischemia | D007511 | EFO_0000556 | — | — | — | — | 1 | 1 | 2 |
| Peripheral arterial disease | D058729 | EFO_0004265 | — | — | — | — | 1 | 1 | 2 |
| Peripheral vascular diseases | D016491 | EFO_0003875 | I73.9 | — | — | — | 1 | 1 | 2 |
Show 2 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Systemic scleroderma | D012595 | EFO_0000717 | M34.0 | — | 3 | 3 | — | 4 | 9 |
| Diffuse scleroderma | D045743 | EFO_0000404 | — | — | 3 | 3 | — | 4 | 9 |
| Sclerosis | D012598 | — | — | — | 2 | 2 | — | 3 | 7 |
| Congenital heart defects | D006330 | HP_0001627 | Q24.9 | 1 | 2 | 1 | — | 3 | 6 |
| Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | 2 | 3 | 1 | — | 1 | 6 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | 1 | 1 | — | 3 | 5 |
| Raynaud disease | D011928 | EFO_1001145 | I73.0 | — | 1 | 2 | — | 1 | 4 |
| Newborn respiratory distress syndrome | D012127 | — | P22 | 2 | 1 | 1 | — | 1 | 4 |
| Septic shock | D012772 | — | A48.3 | — | 2 | 2 | — | — | 3 |
| Shock | D012769 | — | R57.1 | — | 2 | 2 | — | — | 3 |
Show 11 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 1 | 2 | — | — | 3 | 6 |
| Respiratory insufficiency | D012131 | HP_0002093 | J96.9 | 1 | 4 | — | — | — | 4 |
| Pulmonary infarction | D054060 | EFO_1001408 | — | — | 1 | — | — | 1 | 2 |
| Covid-19 | D000086382 | — | — | — | 2 | — | — | — | 2 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | 1 | — | — | — | 1 |
| Arteriosclerosis | D001161 | EFO_0009086 | I70 | — | 1 | — | — | — | 1 |
| Arterial occlusive diseases | D001157 | EFO_0009085 | — | — | 1 | — | — | — | 1 |
| Sepsis | D018805 | HP_0100806 | A41.9 | — | 1 | — | — | — | 1 |
| Pneumonia | D011014 | EFO_0003106 | — | — | 1 | — | — | — | 1 |
| Healthy volunteers/patients | — | — | — | 1 | 1 | — | — | — | 1 |
Show 12 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypoxia | D000860 | HP_0012418 | R09.02 | 2 | — | — | — | — | 2 |
| Lung injury | D055370 | — | S27.30 | 1 | — | — | — | — | 1 |
| Asthma | D001249 | EFO_0000270 | J45 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ulcer | D014456 | MPATH_579 | — | — | — | — | — | 3 | 3 |
| Eisenmenger complex | D004541 | — | I27.83 | — | — | — | — | 2 | 2 |
| Skin ulcer | D012883 | HP_0200042 | L98.4 | — | — | — | — | 2 | 2 |
| Localized scleroderma | D012594 | EFO_1001361 | L94.0 | — | — | — | — | 1 | 1 |
| Coronary artery disease | D003324 | — | I25.1 | — | — | — | — | 1 | 1 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | — | 1 | 1 |
| Insulin resistance | D007333 | HP_0000855 | — | — | — | — | — | 1 | 1 |
| Hypersensitivity | D006967 | HP_0012393 | T78.40 | — | — | — | — | 1 | 1 |
| Respiratory aspiration | D053120 | EFO_1001839 | — | — | — | — | — | 1 | 1 |
| Video-assisted thoracic surgery | D020775 | — | — | — | — | — | — | 1 | 1 |
Show 4 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Iloprost |
| INN | iloprost |
| Description | Iloprost is a carbobicyclic compound that is prostaglandin I2 in which the endocyclic oxygen is replaced by a methylene group and in which the (1E,3S)-3-hydroxyoct-1-en-1-yl side chain is replaced by a (3R)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl group. A synthetic analogue of prostacyclin, it is used as the trometamol salt (generally by intravenous infusion) for the treatment of peripheral vascular disease and pulmonary hypertension. It has a role as a platelet aggregation inhibitor and a vasodilator agent. It is a monocarboxylic acid, a secondary alcohol and a carbobicyclic compound. |
| Classification | Small molecule |
| Drug class | prostaglandins |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC#CCC(C)[C@H](O)/C=C/[C@@H]1[C@H]2C/C(=C/CCCC(=O)O)C[C@H]2C[C@H]1O |
Identifiers
| PDB | — |
| CAS-ID | 78919-13-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL494 |
| ChEBI ID | 63916 |
| PubChem CID | 5311181 |
| DrugBank | DB01088 |
| UNII ID | JED5K35YGL (ChemIDplus, GSRS) |
Target
Agency Approved
PTGIR
PTGIR
Organism
Homo sapiens
Gene name
PTGIR
Gene synonyms
PRIPR
NCBI Gene ID
Protein name
prostacyclin receptor
Protein synonyms
PGI receptor, PGI2 receptor, prostaglandin I2 (prostacyclin) receptor (IP), Prostaglandin I2 receptor, Prostanoid IP receptor
Uniprot ID
Mouse ortholog
Ptgir (19222)
prostacyclin receptor (Q52KE5)
Alternate
PTGER4
PTGER4
PTGER2
PTGER2
PTGER3
PTGER3
PTGDR
PTGDR
TBXA2R
TBXA2R
PTGFR
PTGFR
PTGER1
PTGER1
Organism
Homo sapiens
Gene name
PTGER4
Gene synonyms
PTGER2
NCBI Gene ID
Protein name
prostaglandin E2 receptor EP4 subtype
Protein synonyms
PGE receptor, EP4 subtype, PGE2 receptor EP4 subtype, prostaglandin E receptor 4 (subtype EP4), Prostanoid EP4 receptor
Uniprot ID
Mouse ortholog
Ptger4 (19219)
prostaglandin E2 receptor EP4 subtype (P32240)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 5,451 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
9,158 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use